Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 165, Issue 2, 2012, Pages 135-140

  Talaulikar, Vikram Sinai ^a   Manyonda, Isaac ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Fibroids; PRM; Progesterone receptor modulators

Indexed keywords

ASOPRISNIL; CP 8947; LEVONORGESTREL; MATRIX METALLOPROTEINASE; MIFEPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; TELAPRISTONE ACETATE; TISSUE INHIBITOR OF METALLOPROTEINASE; ULIPRISTAL; UNCLASSIFIED DRUG;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO DEVELOPMENT; ENDOMETRIUM; GENE EXPRESSION REGULATION; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAMMARY GLAND; MENORRHAGIA; METRORRHAGIA; OVULATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION; TREATMENT DURATION; UTERUS MYOMA;

EID: 84870292818     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2012.07.023     Document Type: Review

References (52)

1. L.A. Wise, J.R. Palmer, E.A. Stewart, and L. Rosenberg Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study Obstetrics and Gynecology 105 2005 563 568
2. W.J. Walker, and P. Barton-Smith Long-term follow-up of uterine artery embolisation - an effective alternative in the treatment of fibroids British Journal of Obstetrics and Gynaecology 113 2006 464 468
3. P. Seinera, R. Arisio, A. Decko, C. Farina, and F. Crana Laparoscopic myomectomy: indications, surgical technique and complications Human Reproduction 12 1997 1927 1930
4. A. Davies, R. Hart, and A.L. Magos The excision of uterine fibroids by vaginal myomectomy: a prospective study Fertility and Sterility 71 1999 961 964
5. J.B. Spies, J.M. Cooper, R. Worthington-Kirsch, J.C. Lipman, B.B. Mills, and J.F. Benenati Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multi-centre study American Journal of Obstetrics and Gynecology 191 2004 22 31
6. J. Hindley, W.M.W. Gedroyc, and L. Regan MRI guidance of focused ultrasound therapy of uterine fibroids: early results AJR 183 2004 1713 1719
7. T.T. Carpenter, and W.J. Walker Pregnancy following uterine artery embolisation for symptomatic fibroids: a series of 26 completed pregnancies BJOG 112 2005 321 325
8. National Institute for Clinical Excellence. Guide to the methods of technology appraisal (ref N0515). National Institute for Clinical Excellence UK, April 2004.
9. E.A. Wilson, F. Yang, and E.D. Rees Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue Obstetrics and Gynecology 55 1980 20 24
10. T. Tamaya, J. Fujimoto, and H. Okada Comparison of cellular levels of steroid receptors in uterine leiomyomas and myometrium Acta Gynaecologica Scandinavica 64 1985 307 309
11. P.H. Giangrande, and D.P. McDonnell The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene Recent Progress in Hormone Research 54 1999 291 313
12. I.M. Spitz Clinical utility of progesterone receptor modulators and their effect on the endometrium Current Opinion in Obstetrics and Gynecology 21 2009 318 324
13. T. Maruo, H. Matsuo, and T. Samoto Effects of progesterone on uterine leiomyoma growth and apoptosis Steroids 65 2000 585 592
14. Royal College of Obstetricians and Gynaecologists The management of menorrhagia in secondary care 1999 RCOG Press London [Evidence-based clinical guideline No. 5]
15. S.G. Silverberg, M. Haukkamaa, H. Arko, C.G. Nilsson, and T. Luukkainen Endometrial morphology during long term use of levonorgestrel releasing intra-uterine devices International Journal of Gynaecological Pathology 5 1986 235 241
16. G.A. Irvine, M.B. Campbell-Brown, M.A. Lumsden, A. Heikkilä, J.J. Walker, and I.T. Cameron Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia British Journal of Obstetrics and Gynaecology 105 1998 592 598
17. P. Lähteenmäki, M. Haukkamaa, and J. Puolakka Open randomised study of use of levonorgestrel releasing intrauterine system as an alternative to hysterectomy BMJ 316 1998 1122 1126
18. R. Hurskainen, J. Teperi, and P. Rissanen Quality of life and cost effectiveness of levonorgestrel releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial Lancet 357 2001 273 277
19. R. Hurskainen, J. Teperi, and P. Rissanen Clinical outcomes and costs with the levonorgestrel- releasing intrauterine system or hysterectomy for treatment of menorrhagia. Randomised trial 5-year follow up JAMA 291 2004 1456 1463
20. T. Maruo, J.B. Laoag-Fernandez, P. Pakarinen, H. Murakoshi, I.M. Spitz, and E. Johansson Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium Human Reproduction 16 2001 2103 2108
21. T. Maruo, N. Ohara, and H. Matsuo Effects of levonorgestrel-releasing IUS ands progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas Contraception 75 2007 S99 S103
22. National Collaborating Centre for Women's and Children's health Heavy menstrual bleeding: clinical guideline CG 44 2007 National Institute for Clinical Excellence UK London
23. N. Ohara, Q. Xu, H. Matsuo, and T. Maruo Progesterone and progesterone receptor modulator in uterine leiomyoma growth T. Maruo, H. Mardon, C. Stewart, Translational research in uterine biology 2008 Elsevier Amsterdam
24. N. Ohara, A. Morikawa, and W. Chen Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells Reproductive Science 14 8 Suppl 2007 20 27
25. Q. Xu, N. Ohara, and J. Liu Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells Molecular Human Reproduction 14 2008 181 191
26. W.H. Catherino, M. Malik, P. Driggers, S. Chappel, J. Segars, and J. Davis Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium Journal of Steroid Biochemistry and Molecular Biology 122 2010 279 286
27. S. Yoshida, N. Ohara, and Q. Xu Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth Seminars in Reproductive Medicine 28 2010 260 273
28. I.M. Spitz Progesterone receptor antagonists E. Ottow, H. Weinmann, Nuclear receptors as drug targets 2008 Wiley-VCH Weinheim
29. J. Wilkens, K. Chwalisz, and C. Han Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy Journal of Clinical Endocrinology and Metabolism 93 2008 4664 4671
30. I.M. Spitz, R.D. Wiehle, and A. van As Progesterone receptor modulators in endometriosis: a new therapeutic option J. Garcia-Velasco, B. Rizk, Textbook of endometriosis 2009 Jaypee Brothers Medical Publishers Ltd India
31. N. Chabbert-Buffet, A. Pintiaux-Kairis, and P. Bouchard Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial Journal of Clinical Endocrinology and Metabolism 92 2007 3582 3589
32. K. Chwalisz, W. Elger, T. Stickler, C. Mattia-Goldberg, and L. Larsen The effects of one-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in normal women Human Reproduction 20 2005 1090 1099
33. K. Chwalisz, L. Larsen, C. Mattia-Goldberg, A. Edmonds, W. Elger, and C.A. Winkel A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata Fertility and Sterility 87 2007 1399 1412
34. V. De Leo, G. Morgante, and A. La Marca A benefit-risk assessment of medical treatment for uterine leiomyomas Drug Safety 25 2002 759 779
35. S.H. Eisinger, S. Meldrum, K. Fiscella, H.D. le Roux, and D.S. Guzick Low-dose mifepristone for uterine leiomyomata Obstetrics and Gynecology 101 2003 243 250
36. I.M. Spitz, S. Grunberg, N. Chabbert-Buffet, T. Lindenberg, H. Gelber, and R. Sitruk-Ware Management of patients receiving long term treatment with mifepristone Fertility and Sterility 84 2005 1719 1726
37. K. Fiscella, S.H. Eisinger, and S. Meldrum Effect of Mifepristone for symptomatic leiomyomata on quality of life and uterine size Obstetrics and Gynecology 108 2006 1381 1387
38. J.L. Carbonell Esteve, R. Acosta, B. Heredia, Y. Pérez, M.C. Castañeda, and A.V. Hernández Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial Obstetrics and Gynecology 112 2008 1029 1036
39. R.D. Wiehle, J. Goldberg, T. Brodniewicz, K. Jarus-Dziedzic, and Z. Jabiry-Zieniewicz Effects of a new progesterone receptor modulator CDB-4124, on fibroid size and uterine bleeding, US Obstetrics and Gynecology 3 2008 17 http://www.touchbriefings.com
40. P.K. Brahma, K.M. Martel, and G.M. Christman Future directions in myoma research Obstetrics and Gynecology Clinics of North America 33 2006 199 224
41. K. Chwalisz, R. Lamar Parker, S. Williamson, L. Larsen, K. McCrary, and W. Elger Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867 Journal of the Society for Gynecologic Investigation 10 2 2003 [abstract 636]
42. K. Chwalisz, L. Larsen, K. McCrary, and A. Edmonds Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata Journal of the Society for Gynecologic Investigation 11 2004 320A 321A
43. E.D. Levens, C. Potlog-Nahari, and A.Y. Armstrong CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial Obstetrics and Gynecology 111 2008 1129 1136
44. L.K. Nieman, W. Blocker, and T. Nansel Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study Fertility and Sterility 95 767-772 2011 e1 e2
45. J. Donnez, T.F. Tatarchuk, and P. Bouchard PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery New England Journal of Medicine 366 2012 409 420
46. J. Donnez, J. Tomaszewski, and F. Vázquez PEARL I Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids New England Journal of Medicine 366 2012 421 432
47. F.M. Horne, and D.L. Blithe Progesterone receptor modulators and the endometrium: changes and consequences Human Reproduction Update 13 2007 567 580
48. G.L. Mutter, C. Bergeron, and L. Deligdisch The spectrum of endometrial pathology induced by progesterone receptor modulators Modern Pathology 21 2008 591 598
49. A.R. Williams, H.O. Critchley, and J. Osei The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata Human Reproduction 22 2007 1696 1704
50. O.B. Ioffe, R.J. Zaino, and G.L. Mutter Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator Modern Pathology 22 2009 450 459
51. F. Lakha, P.C. Ho, and Z.M. Van der Spuy A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel) Human Reproduction 22 2007 2428 2436
52. D.T. Baird, A. Brown, H.O. Critchley, A.R. Williams, S. Lin, and L. Cheng Effect of long-term treatment with low-dose mifepristone on the endometrium Human Reproduction 18 2003 61 68